Evidence map›Paper›PMID 31731663›Full record

ArticleInternational journal of molecular sciences2019

A Single Synonymous Variant (c.354G>A [p.P118P]) in

Ryan Hunt, Gaya Hettiarachchi, Upendra Katneni, Nancy Hernandez, David Holcomb, Jacob Kames, Redab Alnifaidy, Brian Lin, Nobuko Hamasaki-Katagiri, Aaron Wesley and 11 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 7 institutions in 2 countries.

Ryan HuntHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Gaya HettiarachchiHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Upendra KatneniHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.ORCID 0000-0002-8145-8894
Nancy HernandezHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.ORCID 0000-0002-8307-4704
David HolcombHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Jacob KamesHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Redab AlnifaidyHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Brian LinHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Nobuko Hamasaki-KatagiriHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Aaron WesleyGene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Tal KafriGene Therapy Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Christina MorrisBioPharmaSpec Ltd., St. Saviour JE2 7LA, UK.
Laura BouchéDepartment of Life Sciences, Imperial College London, South Kensington Campus, London SW7 2AZ, UK.
Maria PanicoBioPharmaSpec Ltd., St. Saviour JE2 7LA, UK.
Tal SchillerHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Juan IblaDepartments of Cardiac Surgery and Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital and Harvard Medical School, Boston, MA 02115, USA.
Haim BarDepartment of Statistics, University of Connecticut, Storrs, CT 06269, USA.ORCID 0000-0002-5496-9699
Amra IsmailCenter for Gene Regulation in Health and Disease, Department of Biological, Geological & Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA.
Howard MorrisBioPharmaSpec Ltd., St. Saviour JE2 7LA, UK.
Anton KomarCenter for Gene Regulation in Health and Disease, Department of Biological, Geological & Environmental Sciences, Cleveland State University, Cleveland, OH 44115, USA.ORCID 0000-0003-4188-0633
Chava Kimchi-SarfatyHemostasis Branch, Division of Plasma Protein Therapeutics, Office of Tissues and Advanced Therapies, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD 20993, USA.
Center for Biologics Evaluation and Research · USBioPharm (United Kingdom) · GBCleveland State University · USUniversity of North Carolina at Chapel Hill · USBoston Children's Hospital · USStevenage Bioscience Catalyst · GBUniversity of Connecticut · US

Funding

Nonintegrating Lentiviral Vectors Towards Clinical TrialsR01DK058702 · NIDDK · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAFRI, TAL · 2001 to 2019
$5.0M
Lentiviral Vector-Based Gene Therapy and The Host Genetic BackgroundR01HL128119 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KAFRI, TAL · 2015 to 2018
$3.0M
Understanding the impact of disease causing mutations in FIXR15HL121779 · NHLBI · CLEVELAND STATE UNIVERSITY · PI KOMAR, ANTON A. · 2014 to 2014
$437k
Department of Energy Not ApplicableNHLBI NIH HHS R01 HL128119NHLBI NIH HHS R15 HL121779NIDDK NIH HHS R01 DK058702NIH HHS 1R15HL121779-01A1The American Heart Association 13GRNT17070025U.S. Food and Drug Administration MODSCI
6 · The paper itself

Abstract

Synonymous variants within coding regions may influence protein expression and function. We have previously reported increased protein expression levels ex vivo (~120% in comparison to wild-type) from a synonymous polymorphism variant, c.354G>A [p.P118P], of the

Indexed as

ADAMTS13 ProteinCircular DichroismHEK293 CellsHumansMass SpectrometryProtein Processing, Post-TranslationalRibosomesADAMTS13 ProteinADAMTS13 protein, humanADAMTS13codon usagepost-translational modificationsribosome profilingspecific activitysynonymous varianttranslation

Identifiers

PMID31731663
PMCPMC6888508
OpenAlexW2984853652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.